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1. Introduction 
 
 
 
 
 
 
 
 
           
 INTRODUCTION 
 During the past years the prevalence of cirrhosis and hence 
portal hypertension has increased. Complications of portal 
hypertension rank among the leading cause of death in cirrhosis 
patients. Among these complications, esophageal variceal bleeding 
remains the most serious outcome. 50-60% of patients with portal 
hypertension develop cirrhosis and around 30% bleed from 
esophageal varices. Mortality rate in case of variceal bleeding is 
around 20-30% and can exceed 50% in some countries. Patients with 
variceal bleeding for the first episode who had no treatment for it have 
a 60% risk of rebleeding
1
. 
 Endoscopic treatment modalities widely used are endoscopic 
sclerotherapy and band ligation for the treatment of acute variceal 
bleeding and for secondary prophylaxis
2
. Both treatment modalities 
have their own advantages and disadvantages. Due to the fact that 
banding therapy has lower rates of complications such as rebleeding, 
mortality and esophageal stenosis, this method has been considered as 
the treatment of choice for esophageal varices by some authors
3
.  
However, a meta-analysis study by Triantos et al., have shown that 
sclerotherapy was superior in efficacy to banding ligation
4
.   Also 
some studies have shown both the methods are equally effective
5
.       
           
 The different opinions shown in various studies regarding the 
treatment of choice for esophageal varices, motivated us to do the 
current study.  Thereby in this study we compared the results of 
endoscopic banding and endoscopic sclerotherapy with 3% sodium 
tetradecyl suphate in the management of esophageal varices.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
2. Aims & objectives  
 
 
 
 
 
 
 
 
           
 
 
 
AIM AND OBJECTIVES 
 
To compare the efficacy of endoscopic variceal ligation and 
endoscopic sclerotherapy in the management of variceal bleeding due  
to portal hypertension. 
 
 
 
 
 
                                  
                                   
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
3. Review of literature 
 
 
 
 
 
 
 
 
           
REVIEW OF LITERATURE 
ESOPHAGEAL VARICES: 
 Esophageal varices are defined as dilated submucosal veins in 
the lower one third of esophagus. They are due to portal hypertension 
most often due to cirrhosis of liver. Variceal bleeding is one of the 
most dreaded complications of portal hypertension and it occurs in 
nearly 30% of patients with chronic liver disease
6
. 
 Hemorrhage from esophageal varices can be treated by 
endoscopic, medical and surgical therapy. But therapy by endoscopic 
methods is the optimal first line treatment for acutely bleeding varices 
as well as subsequent long term management to prevent rebleeding.    
GRADING: 
 I – visible veins but not elevated 
 II – large and raised veins but not touching each other 
 III – raised and tortuous veins almost touching each other 
 IV – very large veins filling the entire lumen  
ANATOMY OF ESOPHAGUS:      
  It is a muscular hollow organ of about 25 cm in length 
extending from pharynx at lower border of cricoid cartilage at the 
level of C6 vertebra to the stomach at T11 thoracic vertebra. It 
descends along the vertebral column and mediastinum, piercing the 
diaphragm ending at the cardiac orifice of the stomach. Esophagus 
           
also presents flexures corresponding to the curvatures in the cervical 
and thoracic vertebral column which is the narrowest part of the 
esophagus. 
    
 
 
Figure 1:  Anatomy of esophagus 
 
 
           
 
RELATIONS: 
         CERVICAL: 
   Anterior: 
 Trachea  
 Thyroid gland 
   Posterior: 
 Vertebral column 
 Longus colli muscle 
   On either side: 
 Common carotid artery 
 Part of lobes of Thyroid gland 
 Recurrent laryngeal nerve 
On Left: 
 Thoracic duct 
         THORACIC: 
   Anterior: 
 Trachea  
 Aortic arch 
 Left bronchus 
 Pericardium 
    
           
 
Posterior: 
 Vertebral column 
 Longus colli muscle 
 Right Posterior intercostal arteries 
 Hemiazygos vein 
 Thoracic duct 
   Left: 
 Left Subclavian artery 
 Thoracic duct 
 Left Pleura 
 Left Recurrent laryngeal nerve 
 Descending thoracic aorta 
   Right: 
 Right Pleura 
 Azygos vein 
 Vagus nerve 
         ABDOMINAL PORTION: 
      It is about 1.25 cm and situated in the posterior surface of lef 
lobe of liver in the esophageal groove. 
 
 
           
HISTOLOGY: 
        It consists of four layers 
 Mucosa 
 Submucosa  
 Muscular layer 
 Outer fibrous layer 
 It lacks serosa 
   MUCOSA: 
 - lined with squamous columnar epithelium and has 4 layers 
 Epithelium 
 Basement membrane 
 Lamina propria 
 Muscularis mucosa 
 
Figure 2: Layers of esophagus 
           
 
Z LINE: 
 It is the transition of esophageal mucosa to columnar epithelium 
in the distal 2 cm of esophagus. 
SUBMUCOSA: 
 It is the red carpet for malignancies since abundant network of 
vascular and lymphatic structures with Meissner's neural plexus. This 
is the layer in which dilatation of veins in esophageal varices occurs. 
MUSCULARIS PROPRIA: 
 It consists of 2 layers 
 Outer Longitudinal 
 Inner Circular 
 Between these muscle layers, a thin septum consists of network 
of ganglia called Auerbach's plexus. 
GASTRO ESOPHAGEAL JUNCTION: 
 There are four anatomic points to identify GEJ 
 2 Endoscopic 
 2 External 
    Endoscopically 
 Z line provided patient does not have Barret's 
esophagus 
           
 Transition from smooth esophageal lining to rugae 
of stomach 
 
 
Figure 3:Gastro esophageal junction on endoscopy 
 
 
   
Figure 4: Gastro esophageal junction 
           
Externally 
 Collar of Helvetius (Willis Loop) 
      It is the region where the circular muscle fibre of the esophagus 
joins the oblique fibre of the stomach 
 Gastro esophageal  fat pad 
BLOOD SUPPLY: 
 
 
 
 
Figure 5: Arterial supply of esophagus 
 
 
           
Arterial supply: 
 Cervical – Inferior thyroid artery 
 Thoracic – 4-6 Esophageal artery from Aorta 
                                        Esophageal branch from Right and Left        
                               Bronchial arteries 
 Abdominal – Left Gastric artery 
                         Inferior Phrenic artery 
 The arteries end in a fine capillary network before penetrating 
the muscular wall. After penetrating the muscularis propria, capillary 
network continues throughout the length of the esophagus within the 
submucosal layer. 
Venous drainage: 
 The venous drainage corresponds to the arteries. Rich 
submucous venous plexus is the first bin for venous drainage. In 
Cervical esophagus, submucous venous plexus drain Inferior Thyroid 
vein which in turn into Left Subclavian and Right brachiocephalic 
vein 
 In Thoracic esophagus, the submucous venous plexus joins with 
more superficial esophageal venous plexus and venae comitantes and 
envelop the esophagus. These plexus in turn drain into Hemiazygos 
and Azygos veins. 
 
           
 
Figure 6: Venous drainage of esophagus 
 
    Abdominal esophageal veins drain into both systemic and portal 
venous system through the right phrenic vein and left gastric vein 
(coronary and short gastric vein respectively). 
LYMPHATICS: 
    It consists of two interconnecting lymphatic plexus arising from 
the submucous and muscularis layer. In the upper two-third of 
esophagus, the lymphatics flow upwards and in lower one-third of 
esophagus, lymphatics flow downwards. 
           
NERVE SUPPLY: 
    Esophagus is innervated by both vagus and sympathetic trunk. 
They both form a plexus which contains a group of ganglions between 
the muscular layers and also in the submucous layer.    
EMBRYOLOGY: 
    The development of esophagus begins in the third week of 
gestation and fetus takes its first swallow by fourteenth week. 
 Formation of gut 
 Molecular regulation of the gut 
 Differentiation of the endoderm. 
FORMATION OF GUT: 
  Cephalocaudal and lateral folding of embryo occurs. Thus the 
endoderm lined yolk sac cavity is incorporated into embryo forming 
primitive gut. 
 It is a blind ending tube consisting of foregut, midgut and hind 
gut. Foregut gives rise to esophagus extending from the pharyngeal 
tube up to the liver outgrowth. 
MOLECULAR REGULATION: 
 Differentiation depends on the reciprocal interaction between 
the endoderm of the gut and the surrounding splanchnic mesoderm 
through HOX code. 
 
           
DIFFERENTIATION OF ENDODERM: 
 Epithelium becomes two to five cells thick and remains 
stratified columnar epithelium till sixth to eighth week of gestation. 
By tenth week the stratified columnar becomes ciliated and by tweflth 
week epithelium becomes completely ciliated. Again during fourth 
and fifth month of gestation stratified squamous epithelium replaces 
ciliated columnar epithelium. 
MUSCULAR DEVELOPMENT: 
 The other part of esophagus is formed from mesoderm. By sixth 
week it is surrounded by undifferentiated mesoderm and a circular 
layer of myoblast. Longitudinal and circular muscle fibre appears. 
 Smooth muscle that forms the lower two-third of esophagus 
arises from splanchnic plexus and it is supplied by splanchnic plexus. 
By twelfth and fifteenth week, the striated muscle that forms the upper 
esophagus arises from branchial arches. Muscular proliferation is at its 
high limits during the eleventh and twelfth week. Hence the 
longitudinal muscles are well defined.   
PORTAL HYERTENSION: 
 It is defined as the increase in the hepatic venous pressure 
gradient > 5mm Hg. 
 It may be due to 
 Increased resistance to blood flow through liver 
           
 Increased splanchnic blood circulation due to 
vasodilatation
7 
 Symptoms of portal hypertension occurs once the pressure rises 
above 10mm Hg 
CAUSES OF PORTAL HYPERTENSION: 
 PRE HEPATIC
8
: 
 Portal vein thrombosis 
▪ Congenital 
▪ Sepsis 
▪ Trauma 
 Splenic vein thrombosis   
 Massive splenomegaly (Banti's syndrome) 
 Malignant occlusion 
HEPATIC: 
 PRE SINUSOIDAL 
▪ Schistosomiasis 
▪ Congenital hepatic fibrosis     
 SINUSOIDAL 
▪ Cirrhosis 
▪ Alcoholic hepatitis 
 
           
 POST SINUSOIDAL 
▪ Hepatic sinusoidal obstruction (veno-  
occlusive syndrome) 
  POST HEPATIC: 
 Budd Chiari syndrome 
 Venoocclusive disease 
 Inferior Vena caval webs 
 Cardiac causes 
▪ Restrictive cardiomyopathy 
▪ Severe congestive heart failure 
▪ Constrictive pericarditis 
 Portal vein drains deoxygenated blood from stomach, intestine, 
spleen, pancreas, and gall bladder. It is formed by superior mesentric 
vein and splenic vein. Superior mesentric vein drains entire small 
bowel, ascending colon and a part of descending colon and head of 
pancreas. Inferior mesentric vein joins splenic vein and hence draining 
the transverse colon and part of descending colon and upper two thirds 
of rectum. Thus portal vein receives blood supply from entire 
gastrointestinal tract. 
 Patients with a pressure gradient of >12mm Hg are at high risk 
for variceal bleeding.  
           
The major complications of portal hypertension are 
 massive upper GI bleeding due to ruptyred 
esophageal varices and portal hypertension 
gastropathy 
 Ascites 
 Hepatorenal syndrome 
 Hepatic encephalopathy.    
CLINICAL COURSE OF VARICEAL BLEEDING: 
 Portal hypertension causes porto- systemic collaterals 
development, among which esophageal and gastric varices are 
troublesome, because their rupture causes variceal hemorrhage, which 
is most lethal complications of cirrhosis.  
 90% of cirrhotic patients develop esophageal varices in their 
lifetime and 30% of these will bleed
9
. When cirrhosis is diagnosed, 
about 30%-40% of compensated patients have varices and 60% of 
decompensated have varices. Once cirrhosis is diagnosed, the 
expected incidence of new varices is 5% per year
10
. 
 In course, varices increase in size before they eventually rupture 
and bleed. Rates of progression of varices range from 5% to 30% per 
year
10
. This variability is due to inter-observer variability, selection of 
patients, Decompensated cirrhosis (Child B/C), alcoholic etiology, and 
the presence of red spots in the esophageal varices. 
           
 Once varices have been diagnosed, the annual incidence of 
variceal bleeding is 10%-15% in non-selected patients. The most 
important factors are variceal size, severity of liver dysfunction and 
red wale markings
11
. The North Italian Endoscopy Club (NIEC) index 
allows the classifications of patients into different groups with a 
predicted 1-year bleeding risk. According to the NIEC index, patients 
with small varices and advanced liver disease are at higher risk of 
early bleeding. The probability of bleeding within 1 year in Child-
Pugh class A patients with large varices and red signs is 24%. But in 
Child-Pugh C patients with small varices and no red signs, the 
incidence of bleeding within 1 year is 20%
12
.  
 Variceal size is the most useful predictor for variceal bleeding. 
The risk of bleeding is very low (1-2%) in patients without varices, 
and increases to 5% per year patients with small varices, and increases 
to 15% per year in patients with medium or large varices at diagnosis. 
Red sign is another predictor of variceal bleeding
13
. Variceal size and 
red signs denote the variceal wall tension (radius, wall thickness), 
which is the factor determining variceal rupture. Studies have shown 
that variceal bleeding occurs if the HVPG reaches a threshold value of 
12 mmHg. If the HVPG is reduced (below 12 mmHg or by > 20% of 
the baseline levels), there is a marked reduction in the risk of bleeding, 
development of ascites, spontaneous bacterial peritonitis and death
12
.  
           
         Variceal bleeding is the second most common cause of mortality 
among the cirrhotic patients. In cirrhotic patients, variceal bleeding 
causes 70% of all upper digestive bleeding
14
. Mortality from variceal 
bleeding has greatly decreased from 42% to 6-12% over the last two 
decades according to the Graham and Smith study in 1981
7
. This is     
due to implementation of effective endoscopic and pharmacological 
therapies, transjugular intrahepatic portosystemic shunt (TIPS) and 
improved general medical care. Death occurring within 6 wk from 
hospital admission for variceal bleeding should be considered as a 
bleeding-related death
15
.  
 Immediate mortality from uncontrolled bleeding is about 4% to 
8%. Prehospital mortality from variceal bleeding is around 3%
13
. 
Other causes for mortality are due to infection, kidney failure, hepatic 
encephalopathy, poor liver function, severe portal hypertension with 
HVPG > 20 mmHg, and active bleeding at endoscopy
14
.  
   
MANAGEMENT OF VARICES: 
 Pharmacological 
 Decompressive shunts 
 Devascularisation procedure 
 Endoscopic therapy 
 Liver transplantation 
           
PHARMACOLOGICAL THERAPY: 
 Non cardioselective beta blockers 
 Somatostatin analogue 
 Vasopressin, terlipressin 
NON CARDIOSELETIVE BETA BLOCKERS: 
                 - Propanolol 
                 - Nadolol 
           These drugs were introduced by Lebrec and his colleagues in 
early 1980s to reduce portal hypertension which is the mainstay of 
prophylactic therapy.            
Advantages: 
               It plays a major role in preventing the initial bleed, managing 
acute variceal bleed and also a first line in preventing the rebleeding. 
Disadvantages: 
              It has limited use in patients with heart disease, kidney 
disease, asthma and other lung disease, diabetes and other drug 
allergies.   
SOMATOSTATIN ANALOGUE (OCTREOTIDE): 
                These are synthetic analogues of somatostatin which act by 
inhibiting the release of vasodilatory hormones and also causing                            
splanchnic vasoconstriction which in turn lowers the portal blood flow 
thereby decreasing bleeding and preventing rebleeding.   
           
VASOPRESSIN AND TERLIPRESSIN: 
                 These drugs are used in acute variceal bleeding by reducing 
the portal pressure. Vasopressin has significant side effects with 
systemic vasoconstriction. So it is largely replaced by terlipressin.  
 
DECOMPRESSIVE SHUNTS: 
               Decompression is mostly used as a second line and is 
reserved only who rebleed after endoscopic therapy and beta blockers. 
Surgical shunts are of 3 categories 
 Total shunt 
 Partial shunt 
 Selective shunt 
TOTAL SHUNT: 
 Classic end to side porto caval shunt 
 Side to side porto caval shunt 
               Shunt size need to be at least 10mm in diameter. Both are 
effective in controlling varices but especially end to side shunt is more 
effective than side to side shunt while only the latter is effective in 
controlling ascites
16
. 
DISADVANTAGE: 
         These shunts are associated with increased incidence of Hepatic 
encephalopathy. 
           
PARTIAL SHUNT: 
       Shunt size is about 8mm. Polytetrafluroethylene (PTFE) 
interposition the grafts between portal vein and inferior venacava 
found to be greater than 90% control of varices and maintain portal 
perfusion. 
SELECTIVE SHUNTS: 
Distal Splenorenal Shunt (DSRS): 
            It is the anastamoses between splenic vein with the left renal 
vein after its dysjunction with the superior mesentric vein
17
. Control of 
bleeding and portal perfusion is maintained in more than 95% of 
indviduals. Incidence of hepatic encephalopathy after the shunt is 
around 15%.  
Transjugular intrahepatic porto systemic shunt (TIPS): 
           TIPS was described by Rosch in 1969 but only in 1982 it was 
first used in humans by Dr.Ronald Colapinto. It became successful 
only with development of endovascular stents in 1985. From 1988 the 
procedure has widely being accepted and preferred method for treating 
portal hypertension refractory to medical treatment. Hence TIPS 
widely replaced the surgical portocaval shunt. TIPS is the puncture of 
internal jugular vein, passage of catheter  into one of the major hepatic 
vein(usually right) through the right atrium followed by 
transparenchymal liver puncture to cannulate the portal vein. 
           
Intraparenchymal tract is dilated and is stented with an expandable 
metal stent. Pressures are measured before and after keeping the stent 
and the goal is to attain a pressure difference of less than 10mm Hg 
between portal vein and right atrium. The success rate is high with less 
morbidity.  
             Disadvantage of TIPS is its thrombosis and restenosis which 
necessitates frequent repeat procedures and monitoring. The early 
thrombosis is related to bile duct puncture since the bile is extremely 
thrombogenic, occlusion occurs within the first 24 hrs.  
DEVASCULARISATION PROCEDURES: 
         These operative procedures take care of the variceal bleeding by 
interrupting the inflow to the varices. The effiacy depends on the 
aggressiveness of the procedure. This is popularized in Japan by 
Sugiura, and in Egypt by Hassab and in Mexico by Orozco. The 
components of this procedure include splenectomy, gastric and 
esophageal devascularisation and occasionally esophageal transection.                                                                   
The advantage is that they do not reduce portal hypertension and 
hence maintaining portal perfusion of the cirrhotic liver. The 
disadvantage is relentless recollateralization of varices across the 
esophagus and stomach with risk of rebleeding. 
 
 
           
LIVER TRANSPLANTATION: 
          Variceal bleeding per se is not an indication for liver 
transplantation while the associated ascites and encephalopathy are 
indicators of end stage liver disease and for liver transplantation. The 
timing of transplant is by the severity of the underlying liver disease. 
    
ENDOSCOPIC THERAPY: 
 SCLEROTHERAPY 
 BANDING 
 TISSUE ADHESIVES 
 ENDOLOOPS 
 BALLOON TAMPONADE 
 CYANOACRYLATE GLUE INJECTION 
ENDOSCOPIC SCLEROTHERPY: 
HISTORICAL ASPECTS: 
         Endoscopic sclerotherapy for esophageal varices was first 
reported by two Swedish surgeons Crafoord and Freckner in 1939 in 
19yr old female using Quinine as sclerosant every alternate day for 
one month till the varices obliterated. Then in 1940, a thoracic surgeon 
Moensch at Mayo clinic reported the second case of sclerotherapy. 
However endoscopic sclerotherapy largely ignored until 1970s, when 
Johnston and Rodgers of Ireland reported their fifteen years with 
           
sclerotherapy
6
. Further studies in late 1970s and 1980s established the 
efficacy of injection sclerotherapy. In the above studies they have been 
compared with other treatment modalities of esophageal varices.  
SCLEROSING AGENTS: 
         Sclerosing agents were actually used in 1920s for varicose veins 
of lower limb. The choice of sclerosants depends on the number of 
considerations including the efficacy of the agent, injection technique, 
safety profile, availability and cost.  
         The sclerosing agents available are  
                 SYNTHETIC PRODUCTS 
 Sodium tetradecyl sulphate 
 Polidocanol 
                 FATTY ACID DERIVATIVES 
 Sodium morrhuate 
 Ethonalamine oleate 
                 OTHER AGENTS 
 3% phenol in water 
 5% phenol in oil 
 Absolute alcohol 
 
   
 
           
FACTORS INFLUENCING SCLEROTHERAPY: 
          A number of factors influence the effect of sclerotherapy on 
esophageal varices which includes choice of endoscope, injection 
sites, timing of the injection, amount and type of the sclerosant used 
and the clinical condition of the patient. 
MECHANISM OF ACTION: 
          The mechanisms of action of these agents are poorly defined but 
the effects involve more than simple initiation of the clotting process 
of intimal injury. Autopsy studies showed that the thrombosis of the 
submucosal vessels occur within the first 24 hours along with tissue 
necrosis even in the absence of extravasation of these agents, while 
superficial or deep ulceration occurs after seven days. Submucosal 
fibrosis was seen after one month of sclerotherapy.  
These extravasation effects may be responsible for the long time 
success of sclerotherapy with the development of fibrosis preventing 
the formation of new variceal channels in the adjacent mucosa. Hence, 
procedures which are directed only at the varices often fail because of 
subsequent ligation of collaterals. Sclerotherapy achieves hemostasis 
through a tamponade effect and also by induction of local thrombosis 
followed by sclerosis due to sclerosant.   
  
 
           
SODIUM MORRHUATE: 
         Sodium morrhuate, a sodium salt of the fatty acid in cod liver oil 
was first described in 1933. It is available as 5% solution. It is being 
less irritating to the adjacent tissues than phenol and quinine mixtures 
which were in use at that time. Studies shows rebleeding rate was 
17%, ulcerations were seen in 23%, fever in 28% and pleural effusion 
in 7% and esophagopleural fistula in 4%. Although sodium morrhuate 
appears to be an effective sclerosing agent the incidence of deep post 
sclerosis ulceration and other serious complications is clearly a 
restricting factor in its use. 
ETHANOLAMINE OLEATE: 
         Ethanolamine oleate is derived from oleic acid and is similar in 
physical properties to sodium morrhuate. It is also available in 5% 
solution. Johnston and Rodgers used 5% ethanolamine oleate in their 
experience of 15 years reported rebleeding rate of 7% and a mortality 
of 18%.  
         The most common complications were pyrexia which was seen 
in 39% and retrosternal discomfort which was seen in 30% of patients. 
Even though ethanolamine oleate enjoys a good reputation as a 
sclerosing agent, the data available at present would not appear to give 
this drug a clear advantage in either safety or efficacy over other 
agents.  
           
ALCOHOL: 
          The advantage of alcohol is its easy availability and economy. 
The success rate in controlling the variceal bleed was 92% with a 
rebleed rate of 32%. There is a higher complication rate with an 
intravariceal injection of absolute alcohol most commonly ulcerations. 
Though alcohol may appear to be an effective sclerosing agent, the 
higher incidence of severe retrosternal pain, dysphagia, ulcers and 
stricture is clearly a restricting factor in its use.   
 
PHENOL: 
          Supe in 1994 used 3% aqueous phenol for sclerotherapy of 
esophageal variceal bleeding. Preobliteration variceal bleeding 
appeared in 15% of the patients. Complications such as esophageal 
ulceration, stricture and perforation were observed in 32%, 4.5% and 
1% of the patients respectively. Though it is cheap and freely 
available, because of the high complication rate, use of phenol as a 
sclerosing agent was given up. 
 
 
 
 
 
           
POLIDOCANOL: 
           Hydroxypolyethyoxydodecan (HPD) or polidocanol is 
commercially available as aethoxysclerol.It is a synthetic product 
available in uniform lots. It is marketed as 0.5, 1, 2, 3% solutions. 
Paquet has concluded by his study that 1% polidocanol was associated 
with decreased rate of complications. Deep ulcerations were seen in 
11 patients out of 640 patients, while superficial ulceration occurred in 
30 patients, pleural effusion in 14 patients. Minor complications like 
retrosternal pain were observed in 15% of the patients. Sorensen et al., 
described a higher rate of esophageal stricture (59%) with the use of 
3% polidocanol especially when more treatment sessions and greater 
amount of scerosants were used
18
.  
   
SODIUM TETRADECYL SULPHATE: 
         Sodium tetradecyl sulphate was first suggested as a sclerosing 
agent in1946. Reiner noted that the agents in use at that time, such as 
sodium morrhuate, were soaps of naturally occuring oils and allergic 
reaction did occur ranging from rash to anaphylaxis. Surface activity 
of the fatty acid anions of the soap was believed to be the physical 
activity responsible for thrombosis. This activity was enhanced in this 
synthetic anionic detergent, sodium tetradecyl sulphate.  
           
          Hence being a detergent based chemical, its action is on the 
lipid molecules in the cells of the vein wall which results in the 
destruction of the internal lining of the vein and eventual sclerosis of 
the vein. It is available in the concentrations of 0.2%, 0.5%, 1.0%, 
1.5%, 3.0% solution. 
         Sodium tetradecyl sulphate occurs as white waxy solid. 
Sotradecol is a sterile non pyrogenic solution of sodium tetra decyl 
sulphate which is used as a sclerosing agent. These drugs are widely 
used for varicose veins.   
ADVERSE EFFECTS: 
         Local reactions such as pain, ulceration are common at the site 
of injection. Allergic reactions like asthma, hay fever and anaphylactic 
shock were reported. Systemic reactions reported are headache, 
nausea and vomiting. 
         Six deaths have been reported among which anaphylactic shock 
accounts for four patients, one is due to asthma and the last is due to 
its concomitant use with anti-ovulatory agent.    
         Blenkinsopp showed that 3% STD was efficacious than 1% but 
damage to arterial wall was seen at both 1% and 3% concentrations 
but at a lesser incidence compared to other sclerosants.                    
This is of interest because the bleeding from deep ulcerations 
following sclerotherapy was to be related to arterial damage rather due 
           
to portal hypertension. Post sclerotherapy ulcerations were found to be 
superficial ulcerations and not considered a drawback. Thus sodium 
tetradecyl sulphate can be considered as one of the potent sclerosing 
agent at present.  
 
TECHNIQUE: 
              There is no accepted standard technique for sclerotherapy 
injections. One disparity lies between paravariceal and intravariceal 
injection 
Intravariceal technique: 
                     It is also known as Anglo-American method. Sclerosants 
are directly injected into the varices. All visible varices are injected 
with 1-2ml of sclerosant directly then with 1-2ml 1cm below the 
bleeding site. Then 1 ml of sclerosant is injected at gastroesophaeal 
junction along all the varices. Even though the varices are present 
more proximally injections are placed up to 10cm from 
gastroesophageal junction in 3-5 cm intervals unless a more proximal 
bleeding site is identified since the sclerosant can escape from varix 
into the azygos system and then into pulmonary circulation. Total 
volume of sclerosant should never exceed 20 ml per session or 5 ml 
per varix.            
 
           
Paravariceal technique: 
                       It is also known as European approach. In this 
technique sclerosnt is injected into the adjacent submucosa of the 
visible varices. At first sclerosant is injected at the gastroesophageal 
junction and it is repeated circumferentially up to 10 cm proximally in 
a spiral fashion. The advantage is that it controls bleeding by causing 
subsequent inflammation and fibrosis around the vessel wall while 
preserving vessel patency allowing for portal decompression and also 
preventing the formation of collateral vessels. 
            Sarin et al., used a transparent teflon injector with a needle for 
injection sclerotherapy. If after puncturing the varices, blood could be 
seen to flow up into the teflon injector, it was taken as intravariceal 
injection. He concluded that intravariceal sclerotherapy was superior 
to paravariceal sclerotherapy in the control of active bleeding and for 
total variceal obliteration but paravariceal injection is associated with 
low recurrence rate
19
. Hence a combination of intravariceal and 
paravariceal injection is superior to the above two. 
COMPLICATIONS OF SCLEROTHERAPY: 
EARLY 
-low grade fever 
-dysphagia 
-retrosternal pain 
           
-pleural effusion 
-chest radiographic changes 
DELAYED 
-mucosal ulcerations 
-perforation 
-esophageal strictures 
-acute respiratory distress syndrome 
-mediastinitis 
-pneumothorax 
-pericarditis 
-fistulas 
-esophageal motility disorder 
-mesenteric venous thrombosis 
-bacteremia 
          Sclerotherapy is associated with a wide range of complications 
ranging from transient pyrexia to esophageal perforation resulting in 
death. Complications following sclerotherapy depends on a number of 
factors namely nature of sclerosant used, amount of sclerosant, 
injection site, concentration of the drug and the time interval between 
the sessions. Minor complications like fever, retrosternal pain and 
dysphagia occurs so frequently that these are considered as side 
effects and not as a complication. 
           
ESOPHAGEAL COMPLICATIONS: 
         Esophageal ulceration occurs frequently following emergency 
sclerotherapy. Sarles included the most superficial ulcers too and 
arrived at a 63% incidence of ulceration with 1% sodium tetradecyl 
sulphate. Conversely, Soderlund included only the ulcers that were 
associated with bleeding or were deep enough to prevent further 
sclerotherapy and reported an incidence of 20%. Jasperson reported 
esophageal ulceration in 78% and ulcerogenic bleeding in 14% 
following sclerotherapy with 1% poidocanol. In the presence of deep 
ulcers, further injection should be deferred to prevent esophageal 
perforation. 
         Esophageal perforation is the most dreaded complication and has 
an incidence of 1-7%. These patients may be managed nonoperatively 
with either enteral feeding or parenteral hyperalimentation and a 
course of intravenous antibiotics. Sarles, using 1.5% sodium 
tetradecyl sulphate, noted esophageal perforation in 0.4% of patients, 
while Jasperson reported a 2% incidence of perforation with the use of 
1% polidocanol. 
         The incidence of esophageal strictures ranges from 0.8%, as 
reported by Johnson with the use of ethanolamine oleate to 52% with 
the use of 3% polidocanol. Sorenson's high rate of esophageal 
           
strictures was attributed to the frequency and amount of sclerosant 
used. 
         Transient substernal pain may occur in 50% of patients 
following sclerotherapy. The pain is due to inflammatory mediastinitis 
or esophageal spasm. Chronic dysphagia following sclerotherapy may 
be due to distal esophageal strictures but 4-5% is due to impaired 
motility. Esophageal manometric studies show no decrease in 
esophageal sphincter pressure but show marked abnormalities in 
esophageal peristalsis. 
          Esophageal carcinoma has been reported in one case after 
undergoing nine sessions of sclerotherapy with 3% polidocanol. 
 
REGIONAL COMPLICATIONS: 
          Pulmonary complications due to sclerotherapy range from 
asymptomatic changes on X-ray to pleural effusion, pneumonia and 
ARDS. Hughes reported 60% in incidence of pleural effusion or 
pulmonary infiltrates following sclerotherapy. Pleural effusion 
resolves spontaneously. Pneumonia occurs due to aspiration. The 
development of ARDS occurs with the use of sodium morrhuate. 
Monroe discovered that sodium morrhuate caused transient pulmonary 
hypertension associated with increased flow of protein poor lymph.   
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SEPTIC COMPLICATIONS: 
         20-40% of patients had fever lasting for 24-48 hours following 
sclerotherapy. When fever lasts more than 2 days, the diagnosis of 
sepsis should be made. Transient bacteremia was reported in 16% of 
patients. Pneumococcus, streptococcus and staphylococcus were the 
commonest organisms isolated. The risk of sepsis due to sclerotherapy 
was not related to the amount of sclerosant used, the number of 
sessions, or the cause of the liver disease. Snady demonstrated a 
threefold increase in the incidence of bacteremia if the needle was 
inserted up to 6-8 mm instead of 3-4 mm. The incidence of clinically 
evident sepsis after sclerotherapy is low, so antibiotic prophylaxis is 
not needed. But Lange and Durack advised endocarditis prophylaxis 
for the patients undergoing sclerotherapy those who have significant 
valvular heart disease. 
         Other septic complications such as brain abscess, spontaneous 
bacterial peritonitis, perinephric abscess, purulent meningitis have 
also been reported. Other complications such as gastric ulcers, 
bleeding duodenal varices, colonic varices, portal vein thrombosis and 
mesenteric vein thrombosis have also been reported. 
 
 
           
   
ENDOSCOPIC VARICEL LIGATION: 
         Endoscopic variceal ligation was first introduced to esophageal 
varices in 1989 by Stiegmann and Goff. This technique is an 
adaptation of the similar banding ligation of internal hemorrhoids. In 
contrast to sclerotherapy where chemical action is used, in variceal 
ligation obliteration of the varices is caused by mechanical 
strangulation with rubber bands. Because of its action on the 
suctioned, entrapped varices, the reaction is usually limited to the 
superficial esophageal mucosa. 
         Endoscopic variceal ligation is the placement of the rubber rings 
over the variceal column which is then sucked into a plastic cylinder 
which is attached to the tip of the endoscope. 
         Previously single shot ligation was used. Multiple shot devices 
have replaced the previous one because of its simplicity and rapidity 
and also over tube is not required and hence preventing its serious 
complications related to its use. And also new transparent caps are 
available which improve the visibility (old caps reduce the visibility 
by 30%). Several commercial multiband devices are available for 
EBL. Multiband devices have 4-10 bands.   
TECHNIQUE: 
           
         Diagnostic endoscopy is performed and varices are identified. 
The distance is measured from the mouth by the markings in the 
endoscope. The endoscope is withdrawn and is loaded with ligation 
devices. Device is firmly attached to the scope and placed in neutral 
mode. Endoscopy with the loading devices is passed which needs little 
experience. Slight flexion of the neck, gentle and constant 
advancement of scope with a slight torque of the shaft right and left 
with visualization of the pharynx would guide it. After intubation the 
device is kept in forward only mode. Once varix is identified, the tip is 
pointed towards it and continuous suction is applied to the varices till 
it is filled in the cap. Smooth movement left and right will help it. 
Once the red out sign appears, band can be fixed. 
          Usually the procedure is performed by starting from 
gastroesophageal junction and proceeding upwards in a spiral fashion 
to avoid circumferential placement at same level which would 
increase risks of stricture. 
          In case of active bleeding the visual field is restricted due to the 
cylinder attachment which makes the technique difficult to perform 
and thus requiring active flushing with water and suction repeatedly.  
The rubber band should be delivered at a point on the varices but if it 
is missed, banding of the normal mucosa is not harmful compared to 
the sclerosant injection, which may cause a serious side effects. 
           
         If the bleeding point is not identified, then a multiple banding 
device can be used to place multiple bands at the gastroesophageal 
junction checking that no subcardial prolongation occurs. This might 
reduce torrential bleeding and then the band can be fixed upward.           
         After the application of rubber bands over the esophageal 
varices, the ligated tissues with the rubber bands will fall off within 10 
days. The variceal sloughing causes shallow esophageal ulcers at the 
ligated sites while the esophageal varices reduce in size. Though the 
ligation induced ulcers have a greater surface area, they are shallower 
and hence heal more quickly than that are caused by sclerotherapy. 
Liquid diet is started for the first 12 hours and then patient is advised 
to have soft foods. A recent study tells that patient who received 
pantaprazole after elective EVL found to have smaller post-banding 
ulcers than the other patients who received placebo therapy on follow 
up endoscopy.  But the symptoms and ulcer number remained the 
same. 
         Eradication of the esophageal varices requires 2-3 sessions of 
endoscopic variceal ligation. De Franchis and Primignani conducted a 
meta-analysis in 1999 included 13 articles in which the mean number 
of sessions to obliterate varices was reduced from 5.4 in patients 
receiving sclerotherapy to 3.6 in patients receiving endoscopic 
variceal ligation. Both the time interval between the sessions and the 
           
number of bands placed in each session should be noted to improve 
the efficacy of banding. Varices is said to be obliterated if they either 
disappear or unable to grasp. Eradication can be obtained in about 
90% of subjects although recurrence is common. The major 
disadvantage is higher incidence of recurrent varices. But these is 
recurrent varices can be treated by ligation. Moreover recurrent 
varices do not increase the chance of rebleeding and do not cause 
endoscopic difficulties. A study from Japan described that EVL 
performed once in two months is better than that is performed in two 
weeks regarding variceal occurrence. Because the rebleeding rate is 
significantly reduced who received endoscopic therapy at early and 
who achieves variceal obliteration in a shorter period. The incidence 
of bacteremia and infectious sequelae are less in EVL compared to 
sclerotherapy. Endoscopic band ligation is an alternate to 
sclerotherapy with less complications but there are the below list of 
complications. 
COMPLICATIONS: 
 Esophageal ulceration  
 Esophageal perforation (due to trauma of over tube) 
 Transient dysphagia 
 Retrosternal pain  
 Esophageal strictures 
           
 Gastropathy 
 Ulcer bleeding 
 Bacteremia 
         The advantage of EVL is the low rate of treatment induced 
complications. This is because the quantity of tissue ligated is limited 
by the design of the device resulting in fewer complications involving 
the esophageal wall
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         Complications of EVL are either due to the ligation procedure or 
from the use of the overtube. Retrosternal pain, transient dysphagia 
occurs frequently in the immediate post ligation period and is 
considered as side effects rather than a complication. 
 
ESOPHAGEAL ULCERATION: 
         The band ligations usually produce small ulcerations and rarely 
produce symptoms. They present as mucosal defects at the site of 
application of bands. 
         Gimson et al., have reported esophageal ulcerations in 36 out of 
54 patients who had banding. 23 of them had small ulcerations (size 
<5mm) and 13 of them were large (size >5mm)
21
. Laine et al., has 
reported esophageal ulcerations producing rebleeding in 5% of 
patients who had undergone ligation. Steigmann has reported bleeding 
from ulcers in 11% of patients following ligation. 
           
          Young et al., compared the ulcerations produced by ligation and 
sclerotherapy by means of scored ERCP cannula to measure the 
length, width and depth of ulcers in a randomized trial. Esophageal 
ligation produced shallow circular ulcerations with large surface area 
that resolved in 14.4 days
22
. Sclerotherapy produced linear, deep 
ulcerations with a smaller surface area that resolved in 20.9 days. 
         Van Vlierberghe et al., reported early rebleeding after ligation in 
patients with Child-Pugh class C cirrhosis. This was attributed to the 
impaired clotting function as a result of liver disease and the greater 
size of the ulcers due to ligation.    
 
ESOPHAGEAL STRICTURES: 
         Esophageal ulcerations leading onto strictures are less common 
following ligation than with sclerotherapy. Laine et al., in a meta-
analysis of 7 randomized trials involving 547 patients found 
esophageal strictures in 7 patients. Another study by Laine et al., 
demonstrated a significant reduction in stricture formation in ligation 
(none) when compared to sclerotherapy (33%). Low rates of stricture 
formation have been reported by Baronicin due to ligation (11%) 
when compared to sclerotherapy. Steigmann and Sarin also reported a 
lower incidence of stricture formation following ligation (2% and 
0%)
23
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ALTERATION OF ESOPHAGEAL MOTILITY: 
         In a study by Berner et al., 75% of patients had reported a 
transient dysphagia which lasted up to 24-72 hours after the 
procedure. This is due to the engorged banded varices. In a study 
conducted by Ming-Chih Hou et al., he compared the alteration of 
esophageal motility following sclerotherapy and ligation. He found 
that ligation produced a little change at 1 month or 3 months after 
eradication, while sclerotherapy produced a significant prolongation 
of transit time for 1month after eradication which was reversible and 
improved after 3 months.   
 
SYSTEMIC COMPLICATIONS: 
         Risk of bacteremia following ligation is 3-6% compared to 
sclerotherapy which is 5-53%. It is associated with fewer episodes of 
infectious sequelae such as spontaneous bacterial peritonitis or 
pneumonia. 
         Gin-Ho et al., reported that infectious sequelae due to 
sclerotherapy is about 18% compared to 1.8% in ligation. This is 
because the mechanical strangulation of varices during ligation 
obliterates the submucosal channels which diminish the entrance of 
           
bacteria into the blood stream. In a meta-analysis of 7 trials conducted 
by Laine et al., 6 out of 524 patients had pulmonary infection and 5 
had bacterial peritonitis which was significantly lower comparing 
sclerotherapy
3
. 
OVERTUBE ASSOCIATED COMPLICATIONS: 
          In the past during endoscopic ligation using a single shot ligator 
the necessary repeated esophageal intubation with the scope is 
facilitated by a flexible plastic overtube passed over the endoscope. 
Majority of complications reported following ligation are associated 
with the use of oertube. Overtube injury to pharynx and proximal 
esophagus transient vocal cord paralysis, cricopharyngeal perforation, 
proximal esophageal perforation, varix rupture and free esophageal 
perforation have also been reported.          
          Mucosal injury has been reported in 72% of treatment sessions 
in one study. Massive bleeding has been reported distal to the 
overtube, probably due to blockage in venous outflow by the tube. 
         Esophageal perforations occurred with over the endoscope 
placement technique because of the large gap between the endoscope 
and the overtube which entrapped esophageal mucosa during the 
process of sliding the overtube over the endoscope during its 
insertion
24
. Since the development of multiband ligator, not a single 
esophageal perforation has been reported. 
           
         Banding is also associated with food impaction resulting from a 
combination of lumen obstruction by banded varices and distal 
esophageal spasm. 
OTHER ENDOSCOPIC OPTIONS: 
TISSUE ADHESIVES (VARICEAL OBTURATION): 
         N-butyl-2-cyanoacrylate and isobutyl-2-cyanoacrylate have been 
used in the control of esophageal and gastric varices with control of 
bleeding in 90% of cases. Tissue adhesives were first used by 
Lunderquist in 1978 in treatment of varices. 
         Cyanoacrylate is a hydrophilic tissue adhesive with a 
consistency similar to water. This when added to blood rapidly 
polymerizes forming a solid cast of the injected vessels which results 
in rapid hemostasis of active bleeding and prevents recurrence of 
bleeding. It has to be diluted with lipid based contrast agent to the 
dilution of about 2:1 ratio to delay the instantaneous polymerization 
within the injection syringe and needle. 
        Complications are due to embolisation of the glue producing 
cerebral stroke, pulmonary embolism, portal vein thrombosis, splenic 
infarction, retrogastric abscess and visceral fistula. Chances of damage 
to endoscope are high due to clogging of the accessory channel. There 
is also danger of eye injury due to accidental spraying of the 
cyanoacrylate. 
           
ENDOLOOPS: 
         Endoloops are detachable nylon snares initially developed to 
control post polypectomy bleeding. This technique has been applied 
for control of bleeding from esophageal varices and reports suggest it 
as a safe and effective as banding or sclerotherapy. Pontecarvo and 
Pesce invented the detachable snare, the 'safety snare' in 1986. 
 
 
 
 
 
           
 
   
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
4. Materials & methods: 
 
 
 
 
 
MATERIALS AND METHODS 
         The study was conducted in the Department of General Surgery 
in collaboration with the Department of Medical Gastroenterology and 
           
Department of Medicine, Coimbatore Medical College Hospital from 
September 2011 to August 2012. This study was approved by the 
ethical committee of Coimbatore Medical College Hospital.   
  
STUDY POPULATION: 
         50 patients with portal hypertension who were admitted during 
the study period of September 2011 to August 2012 in medicine and 
surgery wards, with the complaints of hematemesis and/or malena, 
who had Grade 3 and 4 varices without gastric varices and other 
causes of upper GI bleeding in upper GI endoscopy were included in 
this study. 
 
RANDOMISATION: 
         Every alternate patients presenting with above history is divided 
into 2 groups. One group is treated with esophageal banding and other 
group is treated with 3% Sodium tetradecyl sulphate after getting 
informed and written consent from the patient. 
 
  
INCLUSION CRITERIA: 
 Age 21-70 years 
 Both sex 
           
  Patients complaining with hematemesis and/or malena 
 Grade III and IV esophageal varices 
 Due to Portal Hypertension 
 
EXCLUSION CRITERIA: 
 Age < 21 and > 70 
 Non portal hypertension causes of upper GI bleeding 
 Grade I and II varices 
 Gastric or combined Gastric and Esophageal varices 
 Presence of Hepatic Encephalopathy, Hepatorenal 
syndrome and life expectancy less than 48 hours 
 Prior history of endoscopic treatment and shunt operation 
for varices 
 Patients with positive serology for Hepatitis B (HbsAg) 
and C viruses (anti HCV) 
PROCEDURE: 
         Informed consent is obtained from the patient about the 
procedure. Patient is kept in NPO for 6 hours. Xylocaine spray is 
applied over the posterior pharyngeal wall. Diagnostic endoscopy is 
performed. Presence of the culprit grade III and IV varices are 
identified and confirmed. 
GROUP I: 
           
         They are subjected to esophageal variceal banding. Diagnostic 
endoscopy is performed and varices are identified. The distance is 
measured from the mouth by the markings in the endoscope. The 
endoscope is withdrawn and is loaded with ligation devices. Device is 
firmly attached to the scope and placed in neutral mode. Endoscopy 
with the loading devices is passed. After intubation the device is kept 
in forward only mode. Once varix is identified, the tip is pointed 
towards it and continuous suction is applied to the varices till it is 
filled in the cap. Once the red out sign appears, band can be fixed 
starting from gastroesophageal junction and proceeding upwards in a 
spiral fashion. 
GROUP II: 
         They are subjected to endoscopic sclerotherapy treatment. 
Diagnostic endoscopy is done and varices are identified. All visible 
varices are injected with 1-2ml of 3% sodium tetradecyl sulphate 
below the bleeding site directly into the varices and the colour change 
is noted to confirm. Then the adjacent submucosa of the varices is 
injected with 1ml of the sclerosant carefully upto 10cm from 
Gastroesophageal junction proximally in a spiral fashion. Care is  
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taken that not more than 20ml is injected in a single session to a 
patient. 
         Three sessions were planned for every patient in an interval of 3 
weeks. Thereafter patients were reviewed once in a month for a period 
of three months. For each session the number of bands and the amount 
of sclerosant used are recorded. After the procedure all the patients are 
treated with beta blockers. 
         During each visit, patients were assessed for complications such 
as retrosternal pain, esophageal ulcers, strictures, pleural effusion and 
mediastinitis. 
         Esophageal ulcers are defined as depression in the mucosal 
surface with an overlying injury exudate. They were classified as 
superficial if shallow and less than 2cm in diameter and as deep if 
more than 2cm with shaggy border and a greyish necrotic base. Chest 
x-ray was taken if the patients had persistent pain for detection of 
pleural effusion or mediastinitis if symptoms warranted.  
         Fever was defined as oral temperature more than 99 degree F in 
the first 24 hours following therapy. 
         Dysphagia was defined as difficulty in swallowing food and was 
graded into 4 grades. 
 Grade I – Able to swallow both solid and liquid foods but 
with difficulty 
           
 Grade II – Able to swallow liquid foods but not solid 
foods 
 Grade III – Not able to swallow both solid liquid and solid 
foods 
 Grade IV – Absolute dysphagia including inability to 
swallow saliva 
         Esophageal strictures was diagnosed if the patients repoted with 
dysphagia and had evidence of narrowing by endoscopy and barium 
swallow. The efficacy of treatment was assessed in terms of  
 Eradication of varices 
 Number of sessions for variceal eradication 
 Variceal recurrence 
 Rebleeding episodes prior to eradication 
 Associated complications 
         Variceal eradication was defined as the absence of visible 
variceal channels in the distal 5cm of esophagus or presence of only 
mucosal tags
25
. 
         Variceal recurrence was defined as reemergence of variceal 
columns following previous complete eradication. 
          Control of active hemorrhage was defined as absence of 
clinically detectable upper GI bleeding for 48 hours after endoscopic 
variceal ligation was performed for active bleeding
25
. 
           
         Failure of therapy was defined as recurrent variceal bleeding 
after three endoscopic treatment sessions or during the course of 
therapy.  
 
STATISTICAL ANALYSIS: 
          GraphPad Instat software was used for statistical analysis. 
Fisher’s exact test was used for comparing the outcomes of 
endoscopic band ligation therapy and sclerotherapy. A p value of < 
0.05 was considered statistically significant. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
5. Results: 
 
 
 
 
 
 
 
 
 
 
 
           
RESULTS 
In the study population, 29 males and 21 females have undergone 
treatment for varices and the majority were in the age group of 31-50 
years.  
 
Figure 7: Sex distribution of the study population 
 
Figure 8: Age & sex distribution of the study population 
 
           
 
 
AGE & GRADE DISTRIBUTION: 
 
 
Figure 9: Age & variceal grade distribution of the study population 
                 
           As the age progresses grade IV varices was more common than 
grade III at presentation. 
              
 
 
 
 
           
Study group randomization:  
 
Table 1: Banding & sclerotherapy in bleeding varices 
ACTIVELY 
BLEEDING 
VARICES 
 
BANDING 
 
SCLEROTHERAPY 
 
TOTAL 
GRADE 
III 
GRADE 
IV 
GRADE 
III 
GRADE 
IV 
+ 6 4 5 7 22 
- 7 8 7 6 28 
TOTAL 13 12 12 13 50 
 
           22 cases presented with active bleeding during the procedure 
and the remaining 28 patients had no signs of bleeding. Active 
bleeding was more common among male patients. 
 
        
Figure 10: Randomization of actively bleeding Grade III varices for banding & sclerotherpy 
 
           
 
Figure 11: Randomization of actively bleeding Grade IV varices for banding & sclerotherpy 
 
 
Figure 12: Randomization of actively bleeding varices for banding & sclerotherpy 
 
           
NUMBER OF BANDS & AMOUNT OF SCLEROTHERAPY USED 
 
Table 2: Number of bands and amount of sclerotherapy used 
GRADE ACTIVE BLEED TOTAL NO. OF 
BANDS USED 
TOTAL AMT. OF 
SCLEROSANT(ml) 
III + 52 168 
- 42 120 
IV + 44 196 
- 46 120 
TOTAL  194 532 
 
         94 bands were used for grade III varices and 90 bands were used for grade 
IV varices.188 ml of sclerosant is used for grade III varices and 216 ml of 
sclerosant used for grade IV varices 
 
Figure 13: Number of bands used  
 
           
 
 
Figure 14: Amount of sclerosant used 
 
 
          In case of active bleeding the number of bands and the amount 
of sclerotherapy required are found to be more compared to non-
bleeding varices.   
 
                 
 
 
 
 
 
           
 
COMPLICATIONS: 
 
Table 3: Complications of banding & sclerotherapy  
COMPLICATIONS            BANDING SCLEROTHERAPY 
MALE FEMALE MALE FEMALE 
 %  %  %  % 
RETROSTERNAL PAIN 3 10 3 15 5 16.5 6 30 
ODYNOPHAGIA 1 3.3 3 15 4 13.2 8 40 
FEVER 1 3.3 1 5 5 16.5 6 30 
TACHYCARDIA 0 0 2 10 3 10 5 25 
ESOPHAGEAL ULCER 3 10 3 15 9 29.7 4 20 
STRICTURE 0 0 0 0 1 3.3 0 0 
REBLEEDING 2 6.6 1 5 1 3.3 0 0 
FAILURE 0 0 0 0 2 6.6 3 15 
 
 Females had more complications and frequency of hospital visits after 
procedure than males 
 
 
 
 
 
           
RETROSTERNAL PAIN: 
 
Table 4: Comparison of banding vs sclerotherapy and retrosternal pain 
RETROSTERNAL 
PAIN 
BANDING SCLEROTHERAPY TOTAL 
PRESENT 6 11 17 
ABSENT 19 14 33 
TOTAL 25 25 50 
 
               Though retrosternal pain was seen in more number of cases who 
underwent sclerotherapy, the association was not statistically significant (p value 
0.2321). 
                                          RETROSTERNAL PAIN 
 
Figure 15: Comparison of banding vs sclerotherapy and retrosternal pain  
 
Banding Sclerotherapy 
           
ODYNOPHAGIA: 
Table 5: Comparison of banding vs sclerotherapy and odynophagia 
ODYNOPHAGIA BANDING SCLEROTHERAPY TOTAL 
PRESENT 4 12 16 
ABSENT 21 13 34 
TOTAL 25 25 50 
 
               Twelve patients in the sclerotherapy group suffered odynophagia. 
However, there is no statistically significant difference between the two groups (p 
value 0.0322). 
 
 
 
Figure 16: Comparison of banding vs sclerotherapy and odynophagia  
 
           
FEVER: 
 
Table 6: Comparison of banding vs sclerotherapy and fever 
FEVER BANDING SCLEROTHERAPY TOTAL 
PRESENT 2 11 13 
ABSENT 23 14 47 
TOTAL 25 25 50 
 
            Most of the patients who received sclerotherapy had fever, while only two 
patients in the banding group had fever and this difference was statistically 
significant (p value 0.0083). 
 
 
 
Figure 17: Comparison of banding vs sclerotherapy and fever  
           
 
TACHYCARDIA: 
 
Table 7: Comparison of banding vs sclerotherapy and tachycardia 
TACHYCARDIA BANDING SCLEROTHERAPY TOTAL 
PRESENT 2 8 10 
ABSENT 23 17 40 
TOTAL 25 25 50 
 
     The two treatment groups did not have a statistically significant difference 
when tachycardia among two groups was compared (p value 0.0738). 
 
 
 
Figure 18: Comparison of banding vs sclerotherapy and tachycardia  
           
  ESOPHAGEAL ULCER 
 
Table 8: Comparison of banding vs sclerotherapy and esophageal ulcer 
ESOPHAGEAL 
ULCER 
BANDING SCLEROTHERAPY TOTAL 
PRESENT 6 13 19 
ABSENT 19 12 31 
TOTAL 25 25 50 
 
Though esophageal ulcer was seen in more number of cases who underwent 
sclerotherapy, the association was not statistically significant (p value 0.0792) 
                                          
 
 
Figure 19: Comparison of banding vs sclerotherapy and esophageal ulcer  
           
ESOPHAGEAL STRICTURE: 
 
Table 9: Comparison of banding vs sclerotherapy and esophageal stricture 
ESOPHAGEAL 
STRICTURE 
BANDING SCLEROTHERAPY TOTAL 
PRESENT 0 1 1 
ABSENT 25 24 49 
TOTAL 25 25 50 
 
Esophageal stricture was observed only among the sclerotherapy group, however 
it is not a statistically significant difference (p value 0.3124) 
 
 
 
Figure 20: Comparison of banding vs sclerotherapy and esophageal stricture  
 
           
  REBLEEDING 
 
Table 10: Comparison of banding vs sclerotherapy and rebleeding 
REBLEEDING BANDING SCLEROTHERAPY TOTAL 
PRESENT 3 1 4 
ABSENT 22 24 46 
TOTAL 25 25 50 
 
      Banding therapy was associated with bleeding in 2 patients more than the 
sclerotherapy group. However, this difference was not statistically significant (p 
value 0.6022). 
 
Figure 21: Comparison of banding vs sclerotherapy and rebleeding  
 
           
FAILURE: 
 
Table 11: Comparison of banding vs sclerotherapy and failure 
FAILURE BANDING SCLEROTHERAPY TOTAL 
+ 0 6 6 
- 25 19 44 
TOTAL 25 25 50 
 
                  Sclerotherapy was more commonly associated with treatment failure 
than banding (p value 0.0223). 
 
 
Figure 22: Comparison of banding vs sclerotherapy and failure  
 
   
           
 
 
 
 
 
 
 
 
 
 
 
 
6. Discussion: 
 
 
 
 
 
 
 
 
           
DISCUSSION 
         The improvement in the results of the treatment of the variceal 
bleeding might be attributed to better clinical management of the 
above patients. Although in most of the studies performed, 
sclerotherapy is found to be inferior to band ligation for primary and 
secondary prophylaxis for variceal bleeding and also with lot of 
complications compared to banding some studies suggest that both are 
equally efficacious in the treatment of the esophageal varices. In 1986, 
Steigmann and his colleagues introduced band ligation which acts by 
mechanical action by causing strangulation of the variceal cord 
resulting in necrosis and scar formation 7-10 days later. The 
differences in the technique are provided by number of bands used. 
Upto 10 bands can be used in a single session. Since this procedure is 
easy to perform, results are often reproducible without variations. The 
difficult is that ligation of small varices is tedious. 
         But in case of variceal injection of sclerotherapy, which was the 
first endoscopic treatment used approximately 50 years before the 
band ligation, there are numerous variations including the type of 
sclerosant, sclerosing technique, concentration of sclerosing agent, 
injected volume and location of the sclerosant (intravariceal and 
paravariceal is combined) which is the reason for heterogenous results 
of sclerotherapy presented in different publication. And also this 
           
technique requires more experience and significant skill of the 
endoscopist and hence this technique is more operator dependent 
technique rather than banding. 
         Hence the concept of combining ligation with sclerotherapy by 
employing ligation when the varices are large and converting to 
sclerotherapy when the varices become smaller has been put forward 
to maximize the benefits of both the techniques and minimize the 
complications associated with each other. But most of the studies 
which compared ligation and sclerotherapy with ligation alone showed 
no greater benefits
26–28
.  
         A total of 50 patients included in the present study, 60% of the 
patients are in the age group of 31-50 years. Cirrhosis was the most 
common cause for portal hypertension. This was followed by non-
cirrhotic portal fibrosis and extra hepatic portal vein obstruction. In 
the present study, only the patients who had either grade III or grade 
IV varices at presentation are included. Since the patients with grade I 
and grade II varices were not considered for ligation because of the 
technical difficulty in banding.  
                Most of the patient had cirrhosis has their etiology while the 
others had extrahepatic portal venous obstruction. 
  
 
           
CONTROL OF BLEEDING:    
         A meta-analysis is done comparing the use of band ligation and 
3% sodium tetradecyl sulphate and was published in 2006 and consists 
a total of 12 studies and consists a total of 1310 patients. The efficacy 
of endoscopic band ligation for initial hematemesis was found to be an 
average of 97% while that of the endoscopic sclerotherapy was found 
to be an average of 95%. Despite the better results obtained in the 
control of bleeding in band ligation than sclerotherapy, there is no 
difference in the mortality noted. In the present study, the efficacy of 
banding is 96% and that of sclerotherapy is 88%. This excellent 
control of variceal bleeding is comparable to other reports has been 
mentioned by many authors that during active bleeding, presence of 
fresh blood and blood clots obscures the vision leading to difficulty in 
banding. In this study about 22 patients had active bleeding. In that 10 
were subjected to banding and 12 were subjected to sclerotherapy. 
About 1 patient had rebleeding in banding and 3 patients had 
rebleeding who were subjected to sclerotherapy. 
VARICEAL ERADICATION: 
         Several studies on ligation have reported successful eradication 
of varices in 55-93% of patients. Steigmann et al., reported an 
eradication rate of 51% with ligation with a median of 5 treatment 
sessions and 14 ligation per patient. Laine et al., in their study of 38 
           
patients who underwent ligation reported 59% of eradication with a 
median of 4 treatment session at an average of 3.9 bands at each 
session. Gimson et al., reported an eradication rate of 70% in patients 
who underwent ligation with a median of 3.4 endoscopic sessions
21
. 
Sarles et al., reported 28% obliteration rate
29
. In another study, 
variceal obliteration was achieved in 54% of patients who were treated 
with sodium tetradecyl sulphate. Despite these old studies, new 
studies such as Bhargava et al., reported eradication in 87% of patients 
at a median of 6 endoscopic sessions and also showed 88% 
eradication rate in use of sodium tetradecyl sulphate
30
.  
         The King's college study reported a satisfactory eradication of 
esophageal varices by the use of banding with less complication than 
sclerotherapy although much of the complications are strictures. A 
study conducted by Grimson and Ramage et al., with an aim to find 
whether endoscopic variceal ligation is more effective in eradicating 
varices than sclerotherapy showed that both the techniques were 
effective in controlling the bleeding (92% for banding and 91% for 
sclerotherapy). Variceal obliteration was not achieved in some patients 
in each group (3% in banding and 6% in sclerotherapy). Though there 
was no significant difference between the above two techniques in 
eradication, ligation achieved more quickly than sclerotherapy. Thus 
in newer studies, the efficacy of both band ligation and sclerotherapy 
           
in eradicating the varices have increased a lot. This might be due to 
the advancement in the instrumentations and devices such as use of 
multiband ligating devices rather than single band ligating devices. In 
the present study of about 50 patients, 25 were treated by endoscopic 
variceal banding and other 25 patients by endoscopic sclerotherapy 
(3% sodium tetradecyl sulphate), the eradication of varices by banding 
was 100% while that of sclerotherapy was only 80%. As the most of 
the previous studies, the present study also suggests that the 
endoscopic variceal banding is superior to sclerotherapy in the 
eradication of varices.  
COMPLICATIONS: 
         Most of the studies suggest that the main advantage of ligation 
over sclerotherapy is the low rate of complication. Laine et al., have 
reported complication in 24% of patients who had ligation. AlTraif et 
al., have reported a complication rate of 60% using sclerotherapy
28
. In 
the present study, the complications were found in 30 of 50 patients 
among which the majority were esophageal ulceration, retrosternal 
pain, odynophagia, fever and tachycardia. Similar observations were 
made out in most of the studies. The patients who had active bleeding 
during the procedure had more complication rate. 
 
  
           
ESOPHAGEAL ULCER: 
           Esophageal ulcer was the commonest complication following 
sclerotherapy in most of other studies. The occurrence of post 
sclerotherapy ulceration was attributed to the higher volume of 
sclerosant per session, shorter interval between sclerotherapy sessions, 
higher concentration of sclerosant and nature of sclerosant used. In 
case of banding large superficial ulcerations are common due to 
necrosis. Esophageal ulceration was reported in 36% of patients who 
had undergone ligation by Gimson et al., in the study of 54 patients
21
. 
Korula et al., has also shown similar reports- 70% of patient who had 
sclerotherapy. Blenkinsopp et al., showed that diluting sodium 
tetradecyl sulphate from 3% to 1% reduce the rate of ulceration with 
only a minimal decrease in efficacy. Westaby et al., compared the 
effect of sclerotherapy at one weekly interval and at three weekly 
interval and found that ulceration were common in one weekly 
interval. In present study, the esophageal ulceration is found to be the 
most common complication of both banding and sclerotherapy. 6 out 
of 25 patients had esophageal ulceration who underwent variceal 
banding while 13 patients of 25 had esophageal ulceration who 
underwent sclerotherapy. Thus 25% of patients who had banding and 
about 50% of patients who had sclerotherapy developed esophageal 
           
ulceration. All ulceration were found to be superficial without 
bleeding.  
The higher incidence of ulceration in the sodium tetradecyl sulphate 
group was probabaly due to concentration used (3%) and also due to 
ulcerogenic property of sodium tetradecyl sulphate. 
RETROSTERNAL PAIN: 
         Transient retrosternal pain following sclerotherapy can be due to 
mediastinitis and due to esophagitis. Korula et al., reported an 
incidence of 24% with 1.5% sodium tetradecyl sulphate. In a study 
done by Lebski et al., the banding is associated with about 86% of 
patients who underwent the treatment
31
. These results were compared 
to our study in which about 40% of patients developed retrosternal 
pain among which 6 out of 25 patients who underwent banding and 11 
of 25 patients who underwent sclerotherapy had retrosternal pain.  
ODYNOPHAGIA: 
            In a study by Berner et al., 75% of patients had reported a 
transient dysphagia which lasted upto 24-72 hours after the procedure. 
This is due to the engorged banded varices. Bargava et al., noted that 
dysphagia significantly common with sclerotherapy with sodium 
tetradecyl sulphate
30
. In the present study also, odynophagia is more 
commonly seen in sodium tetradecyl sulphate group than banding 
group. The difference was statistically signifcant. Edema and 
           
inflammation around the ulcer contributes to the narrowing of 
esophagus. This explains why dysphagia is more common in use of 
sclerotherapy because of its ulcerogenic property. Hence around 4 
patients of 25 who underwent banding and 12 of 25 patients who 
underwent sclerotherapy had dysphagia with the significant 'P' value 
of < 0.05. 
FEVER: 
         In most of studies, fever lasting for 24-48 hours after 
sclerotherapy and banding occurred in 20-40% of patients. Fever 
usually subsided spontaneously.  In the present study, fever was seen 
in 8% of patients who underwent banding and 44% of patients who 
underwent sclerotherapy with significant 'P' value. Most of the other 
studies have shown similar report with present study. 
TACHYCARDIA: 
         Tachycardia following banding and sclerotherapy could be due 
to febrile spikes or anxiety by the procedure. Kumar et al., reported 
tachycardia in 48% of patient with 3% sodium tetradecyl sulphate. In 
the present study 32% of patients who underwent sclerotherapy had 
tachycardia while only 8% of patients who underwent banding had 
tachycardia. 
      
 
           
ESOPHAGEAL STRICTURE: 
         Esophageal strictures are due to healing of deep esophageal 
ulceration. Bargava et al., reported an incidence of 27% of strictures 
with 1.5% sodium tetradecyl sulphate
30
. Sorensen used 3% sodium 
tetradecyl sulphate and reported strictures in 35% of patients. He 
attributed this higher rate to frequent sclerotherapy sessions. Most of 
other studies reported stricture rate ranging from 1-20%. Laine et al., 
in a meta-analysis of 7 randomized trials involving 547 patients found 
esophageal strictures in 7 patients
3
. Another study by Laine et al., 
demonstrated a significant reduction in stricture formation in ligation 
(none) when compared to sclerotherapy (33%)
32
. Low rates of 
stricture formation have been reported by Baronicin et al., due to 
ligation (11%) when compared to sclerotherapy. Steigmann and Sarin 
also reported a lower incidence of stricture formation following 
ligation (2% and 0%)
19
. In the present study, only one patient with 
stricture has been noted who underwent sclerotherapy four months 
after the procedure. No patients were found to develop stricture 
following banding. This is probably due to proper banding technique 
in a spiral fashion and restricting the sclerotherapy to proximal 10cm 
of gastroesophageal junction.   
 
  
           
 
 
 
 
 
 
 
 
 
 
 
7.Summary: 
 
 
 
 
 
 
 
 
 
           
SUMMARY 
                This study is conducted prospectively on a total of 50 
patients with bleeding esophageal varies from September 2011 to 
August 2012 with the prime aim of evaluating the efficacy and safety 
of endoscopic variceal banding and endoscopic sclerotherapy.   
1. In this study cirrhosis is the most common etiology of portal 
hypertension accounting for 90% of the study population. 
2. 60% of study population were in 31-50 years of age group. 
3. In this study more than 70% of  old age people presented  grade IV 
than grade III varices. 
4. In this study about 45% of patients had signs of active bleeding. 
5. In actively bleeding varices, sclerotherapy has a little added 
advantage over banding because of the technical difficulty of the 
banding due to obscured field. 
6. In this study about 194 bands and 532 ml of sclerosant were used 
with a mean of 7.76 bands and 21.2 ml of sclerosant per person 
respectively. 
7. In actively bleeding varices the mean number of bands and the 
amount of sclerotherapy is more compared to that of mean of number 
of bands and amount of sclerotherapy in non-bleeding patients. 
           
8. In this study more number and percentage of females had 
complications compared to males though the study population of 
females is less. 
9. 24% of patients had retrosternal pain in banding while 44% of 
patients in sclerotherapy had retrosternal pain. 
10.16% of patients with banding and 48% of patients with 
sclerotherapy had odynophagia. 
11.22% of patients with banding and 44% of patients with 
sclerotherapy had fever. 
12. 32% of patients with sclerotherapy had tachycardia. No patients 
with banding complained of tachycardia. 
13. 24% of patients with banding and 52% of patients with 
sclerotherapy had esophageal ulceration.   
14. 4% of patients with sclerotherapy developed stricture.No patients 
with banding developed stricture over the follow up period. 
15. 12% of patients with banding and 3% of patients with 
sclerotherapy had rebleeding during and after the procedures.   
16.  20% of patients with sclerotherapy had recurrences of varices 
while no recurrence was seen in banding for the follow up period. 
17. 'P' value is significant in complications such as odynophagia, fever 
and recurrence. 
 
           
 
 
 
 
 
 
 
 
 
 
 
8. Conclusion: 
 
 
 
 
 
 
 
 
 
           
CONCLUSION 
 
 Both banding and 3% sodium tetradecyl sulphate are equally 
effective in controlling acute variceal hemorrhage among which 
sclerotherapy has a small advantage and also in preventing 
rebleeding. 
 Both banding and sclerotherpy are effective in eradicating varices 
but banding is more efficacious 
 Both banding and sclerotherapy have their side effects but 
sclerotherapy has more frequent and dreaded complications. 
 Hence banding is superior to sclerotherapy both in efficacy and 
safety 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
9. Limitations of the study: 
 
 
 
 
 
 
 
 
 
           
LIMITATION OF THE STUDY 
The limitations of this study are: 
 The numbers of patients studied were small. 
 The period of follow-up of patients was short. 
 The compliance of patients for follow-up was poor. 
 Non-availability of bands lead to exclusion of some patients. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
10. Bibliography: 
 
 
 
 
           
References 
1.  Kuran S, O\uGuz D, Parlak E, Asil M, \cCİ\cCek B, Kili\cC M, et 
al. Secondary prophylaxis of esophageal variceal treatment: 
Endoscopic sclerotherapy, band ligation and combined therapy-
long-term results. Turkish Journal of Gastroenterology 
2006;17:103–9.  
2.  Krige JEJ, Shaw JM, Bornman PC. The evolving role of 
endoscopic treatment for bleeding esophageal varices. World 
journal of surgery 2005;29:966–73.  
3.  Laine L, Cook D. Endoscopic ligation compared with 
sclerotherapy for treatment of esophageal variceal bleeding. A 
meta-analysis. Annals of internal medicine 1995;123:280.  
4.  Triantos CK, Goulis J, Patch D, Papatheodoridis GV, Leandro G, 
Samonakis D, et al. An evaluation of emergency sclerotherapy of 
varices in randomized trials: looking the needle in the eye. 
Endoscopy 2006;38:797.  
5.  Luz GO, Maluf-Filho F, Matuguma SE, Hondo FY, Ide E, Melo 
JM, et al. Comparison between endoscopic sclerotherapy and band 
ligation for hemostasis of acute variceal bleeding. World journal of 
gastrointestinal endoscopy 2011;3:95.  
6.  Tait IS, Krige JEJ, Terblanche J. Endoscopic band ligation of 
oesophageal varices. British Journal of Surgery 1999;86:437–46.  
7.  Bosch J, Abraldes J, Berzigotti A, Garcia-Pagan J. Portal 
Hypertension and Gastrointestinal Bleeding. Seminars in Liver 
Disease 2008;28:003–25.  
           
8.  Johansen K, Helton WS. Portal Hypertension and Bleeding 
Esophageal Varices. Annals of Vascular Surgery 1992;6:553–61.  
9.  Chang YW. Indication of Treatment for Esophageal Varices: Who 
and When? Digestive Endoscopy 2006;18:10–5.  
10. Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the 
modern management of portal hypertension – primary and 
secondary prophylaxis of variceal bleeding in cirrhotic patients. 
Alimentary Pharmacology & Therapeutics 2008;28:178–86.  
11. Bosch J, Abraldes JG, García-Pagán JC. Clinical Manifestations 
and Management of Bleeding Episodes in Cirrhotics [Internet]. In: 
MD JR, MD J-PB, MD ATB, MD JR, MD  rio R, editors. Textbook 
of Hepatology. Blackwell Publishing Ltd; 2008 [cited 2012 Dec 
21].  page 640–57.Available from: 
http://onlinelibrary.wiley.com/doi/10.1002/9780470691861.ch7c/s
ummary 
12. Zhang C, Thabut D, Kamath PS, Shah VH. Oesophageal varices in 
cirrhotic patients: from variceal screening to primary prophylaxis 
of the first oesophageal variceal bleeding. Liver International 
2011;31:108–19.  
13. García-Pagán J, Reverter E, Abraldes J, Bosch J. Acute Variceal 
Bleeding. Seminars in Respiratory and Critical Care Medicine 
2012;33:46–54.  
14. Thabut D, Bernard-Chabert B. Management of acute bleeding 
from portal hypertension. Best Practice & Research Clinical 
Gastroenterology 2007;21:19–29.  
           
15. Md JGA, Md JB. Clinical Features and Natural History of Variceal 
Hemorrhage [Internet]. In: MD AJSM, MD VHS, editors. Portal 
Hypertension. Humana Press; 2005 [cited 2012 Dec 21].  page 
167–81.Available from: 
http://link.springer.com/chapter/10.1007/978-1-59259-885-4_12 
16. Garcia-Tsao G. The transjugular intrahepatic portosystemic shunt 
for the management of cirrhotic refractory ascites. Nature Reviews 
Gastroenterology and Hepatology 2006;3:380–9.  
17. Rosemurgy AS, Zervos EE. Management of variceal hemorrhage. 
Current Problems in Surgery 2003;40:255–343.  
18. Sørensen T, Burcharth F, Pedersen ML, Findahl F. Oesophageal 
stricture and dysphagia after endoscopic sclerotherapy for bleeding 
varices. Gut 1984;25:473–7.  
19. Sarin SK, Nanda R, Sachdev G, Chari S, Anand BS, Broor SL. 
Intravariceal versus paravariceal sclerotherapy: a prospective, 
controlled, randomised trial. Gut 1987;28:657–62.  
20. Stiegmann GV, Goff JS, Michaletz-Onody PA, Korula J, 
Lieberman D, Saeed ZA, et al. Endoscopic Sclerotherapy as 
Compared with Endoscopic Ligation for Bleeding Esophageal 
Varices. New England Journal of Medicine 1992;326:1527–32.  
21. Gimson AES, Ramage JK, Panos MZ, Hayllar K, Harrison PM, 
Williams R, et al. Randomised trial of variceal banding ligation 
versus injection sclerotherapy for bleeding oesophageal varices. 
The Lancet 1993;342:391–4.  
           
22. Young MF, Sanowski RA, Rasche R. Comparison and 
characterization of ulcerations induced by endoscopic ligation of 
esophageal varices versus endoscopic sclerotherapy. 
Gastrointestinal Endoscopy 1993;39:119–22.  
23. Sarin SK, Govil A, Jain AK, Guptan RC, Issar SK, Jain M, et al. 
Prospective randomized trial of endoscopic sclerotherapy versus 
variceal band ligation for esophageal varices: influence on 
gastropathy, gastric varices and variceal recurrence. Journal of 
hepatology 1997;26:826–32.  
24. Dennert B, Ramirez FC, Sanowski RA. A prospective evaluation 
of the endoscopic spectrum of overtube-related esophageal 
mucosal injury. Gastrointestinal Endoscopy 1997;45:134–7.  
25. Stiegmann GV, Goff JS, Sun JH, Hruza D, Matthew Reveille R. 
Endoscopic ligation of esophageal varices. The American Journal 
of Surgery 1990;159:21–6.  
26. Karsan HA, Morton SC, Shekelle PG, Spiegel BMR, Suttorp MJ, 
Edelstein MA, et al. Combination endoscopic band ligation and 
sclerotherapy compared with endoscopic band ligation alone for 
the secondary prophylaxis of esophageal variceal hemorrhage: a 
meta-analysis. Digestive diseases and sciences 2005;50:399–406.  
27. Singh P, Pooran N, Indaram A, Bank S. Combined ligation and 
sclerotherapy versus ligation alone for secondary prophylaxis of 
esophageal variceal bleeding: a meta-analysis. The American 
journal of gastroenterology 2002;97:623–9.  
28. Al Traif I, Fachartz FS, Al Jumah A, Al Johani M, Al Omair A, Al 
Bakr F, et al. Randomized trial of ligation versus combined ligation 
           
and sclerotherapy for bleeding esophageal varices. Gastrointestinal 
endoscopy 1999;50:1–6.  
29. Sarles HE Jr, Sanowski RA, Talbert G. Course and complications 
of endoscopic variceal sclerotherapy: a prospective study of 50 
patients. Am. J. Gastroenterol. 1985;80:595–9.  
30. Bhargava DK, Singh B, Dogra R, Dasarathy S, Sharma MP. 
Prospective randomized comparison of sodium tetradecyl sulfate 
and polidocanol as variceal sclerosing agents. Am. J. 
Gastroenterol. 1992;87:182–6.  
31. Leszczyszyn J, \Lebski I, Massopust R, Skoczylas M, Janus W. 
Results of rubber band ligation of esophageal varices. Medical 
science monitor: international medical journal of experimental and 
clinical research 2001;7:287.  
32. Laine L, El-Newihi HM, Migikovsky B, Sloane R, Garcia F. 
Endoscopic ligation compared with sclerotherapy for the treatment 
of bleeding esophageal varices. Annals of internal medicine 
1993;119:1.  
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
11: Annexure 
 
 
 
 
 
 
 S.NO NAME Ag
e 
Sex IP.NO DIAGNOSIS GRAD
E 
BLEEDIN
G 
NO. OF BANDS          
PER SESSION 
RETRO 
STERNAL 
PAIN 
ODYNOPHAGI
A 
FEVER TACHYCARDI
A 
ULCER STRICTUR
E 
REBLEEDIN
G 
FAILURE 
  I   II   III 
1 Srinivasan  50 M 52652 Cirrhosis III + 6 3 1 + +   +    
2 Neelamani 55 F 57521 Cirrhosis III - 5 1 -         
3 Manoranjitham 22 F 59715 EHPVO IV - 5 1 -         
4 Ganesh 
Moorthy 
48 M 49443 Cirrhosis III + 6 2 1         
5 Chikuthayamma
l 
48 F 60189 Cirrhosis IV + 6 3 2 +  + + +    
6 Ramathal 48 F 54168 Cirrhosis IV + 6 4 1         
7 Kasi 51 M 53238 Cirrhosis IV - 5 1 -         
8 Bannari 42 F 11712 Cirrhosis III - 5 1 -         
9 Karpagam 28 F 26310 Cirrhosis III + 6 2 0         
10 Kalyani 24 F 31521 EHPVO III - 5 1 -         
11 Kulalmani 69 F 35761 Cirrhosis IV - 5 1 -         
12 Palanisamy 52 M 28633 Cirrhosis IV - 5 1 -         
13 Rajendran 42 M 48723 Cirrhosis III + 6 2 -         
14 Alvikutty 40 M 55875 Cirrhosis IV + 6 4 1 +    +  +  
15 Kumar 40 M 54429 Cirrhosis III - 5 1 -         
16 Sivagami 50 F 68952 Cirrhosis IV + 6 3 2 +   + +  +  
17 Kalimuthu 35 M 22986 Cirrhosis III - 5 1 -         
18 Raman 55 M 51489 Cirrhosis IV - 5 - - +  +  +    
19 Neelamani 40 F 53935 Cirrhosis III + 5 4 - +    +    
20 Ravikumar 53 M 38512 Cirrhosis IV - 5 - -         
21 Jaganathan 36 M 32116 Cirrhosis III - 5 1 -         
22 Vimal 22 M 44874 EHPVO IV - 5 1 -         
23 Vinoth 38 M 42023 Cirrhosis IV - 5 1 -         
24 Karthikeyan 26 M 39965 EHPVO IV + 6 2 1       +  
25 Lakshmi 55 F 46713 Cirrhosis III - 5 1 -  +       
  
S.NO NAME Ag
e 
Sex IP.NO DIAGNOS
IS 
GRADE BLEEDIN
G 
3% STD PER 
SESSION 
RETRO 
STERNAL 
PAIN 
ODYNOPHAGI
A 
FEVER TACHYCARDI
A 
ULCER STRICTUR
E 
REBLEEDIN
G 
FAILURE 
  I   II  III 
1 Rajan 65 M 52815 Cirrhosis III + 16 9 8 +  +  +    
2 Ramathal 65 F 57643 Cirrhosis IV - 13 8 5 + + + +     
3 Chandran 41 M 59812 Cirrhosis IV - 10 8 6     +    
4 Zubair 40 M 50617 Cirrhosis III + 15 11 8 + +   +    
5 Ganesh 39 M 61256 Cirrhosis IV + 10 10 8         
6 Palani 58 M 55431 Cirrhosis IV - 11 7 4         
7 Rukmani 49 F 54521 Cirrhosis IV + 15 8 5 + + + + +   + 
8 Muniyandi 52 M 12604 Cirrhosis III - 11 5 2 + + + +     
9 Lakshmi 60 F 27213 Cirrhosis IV + 16 7 4 + + + +     
10 Poongothai 33 F 32698 Cirrhosis III - 10 3 0  + + +     
11 Natraj 43 M 36845 Cirrhosis IV + 17 9 6 + +   +    
12 Sundaram 50 M 29119 Cirrhosis IV - 11 7 6     +    
13 Sugapriya 24 F 49760 EHPVO III + 16 10 9  +   +    
14 Venugopal 65 M 56734 Cirrhosis IV + 13 10 5   + + + +   
15 Sarojini 40 F 55926 Cirrhosis III - 10 2 0 + +       
16 Selval 74 F 69183 Cirrhosis III - 8 2 3        + 
17 Poovathal 50 F 23615 Cirrhosis IV - 10 6 4 + + + +    + 
18 Chittisekar 33 M 52740 Cirrhosis IV + 14 9 3     +    
19 Eswari 40 F 54291 Cirrhosis III - 9 5 1   +      
20 Jeyalaksmi 46 F 41572 Cirrhosis III - 12 5 3 + +       
21 Ravi 48 M 34797 Cirrhosis III + 15 10 9 + +   +  + + 
22 Natraj 52 M 45102 Cirrhosis IV + 14 12 5   + + +   + 
23 Niwaz 26 M 43681 EHPVO IV - 11 3 1   +      
24 Vasanth 36 M 52739 Cirrhosis IV + 10 11 7     +    
25 Thenmozhi 28 F 34065 EHPVO III - 10 3 1     +    
 
ANNEXURE-1 
 
 
PROFORMA 
 
Serial Number: 
          
             Name: 
             Age :                                                           Sex   : 
             Hospital No:                                               Ward : 
             Address  : 
 
 
D.O.A                                               D.O.D                                 D.O.S 
 
I. PRESENTING COMPLAINTS 
 
                   Hemetemesis: 
                 Malena: 
                 Jaundice: 
                 Fever: 
                 Abdominal pain: 
                 Abdominal distension: 
                 Altered sensorium: 
                 Pedal edema: 
                 Drug intake: 
 
II.  PAST HISTORY 
 
                 Hemetemesis: 
                 Malena: 
                 Jaundice: 
                 Alcoholism: 
                 Hypertension: 
 
       PREVIOUS TREATMENT 
             
III. EXAMINATION 
             
                   Built and Nourishment:                                Icterus: 
                    Mental status:                                               Cyanosis: 
                    Pallor:                                                           Clubbing: 
                    Lymphadenopathy: 
                    E/o Liver failure: 
 
  
PR:                            Temp:                         RR:                        BP: 
 
P/A: 
 
       Distension:                                                  Abdominal veins: 
 
        Liver:                                                          Spleen: 
 
        Ascitis: 
 
        Respiratory system: 
 
         CVS:  
 
IV.  INVESTIGATION: 
 
 
Hb: Platelet count: 
TC: Peripherel smear: 
DC:  
Blood Urea: Blood Sugar: 
Na/K: HbsAg: 
Sr.Bilirubin: SGPT: 
SGOT Sr. Alk PO4: 
     
 
 
USG of Abdomen: 
 
 
 
TREATMENT 
                            
              Date: 
              Grade of varices: 
              No. of columns: 
              No. Of bands applied: 
              Amount of sclerosant injected: 
 
                    
 
COMPLICATIONS: 
            
                 Retrosternal Pain: 
 
                 Odynophagia: 
 
                 Fever: 
 
                 Tachycardia: 
 
                 Esophageal ulcer: 
 
                 Esophageal perforation: 
 
                 Pleural effusion: 
 
                 Mediastinitis: 
 
                 Rebleed: 
 
 
FOLLOW UP 
 
 
SESSION 1 2 3 FOLLOW UP 
DATE      
GRADE      
NO. OF COLUMNS      
NO. OF BANDS APPLIED      
AMOUNT OF SCLEROSANT      
COMPLICATIONS  
 
 
 
    
 
CONSENT FORM
It  has  been  explained  to  me  in  my  mother  tongue  and  I 
completely  understand  my  condition,  its  related 
complications  and  the  treatment  options  available.  I  have 
been  explained  in  detail  regarding  this  study-  “A 
COMPARATIVE  STUDY  OF  EFFICACY  AND  SAFETY  OF 
ENDOSCOPIC  BANDING  AND  SCLEROTHERAPY  IN  
ESOPHAGEAL  VARICES ”.  I  hereby  give  my  consent  to 
participate in the above mentioned study.
DATE:
PLACE:
SIGNATURE OF THE RELATIVE     SIGNATURE OF THE PATIENT
WITH NAME :      WITH NAME :
SIGNATURE OF THE WITNESS
WITH NAME :
